Netflix, Eli Lilly & Arm: With these growth stocks, analysts see strong future prospects

• Arm Holdings before quarterly figures: analysts see upward potential
• After a good first quarter: Eli Lilly receives “Strong Buy” from Wall Street expert
• Netflix with a strong financial report: market capitalization of $ 1 billion by 2030?

The markets are currently characterized by geopolitical uncertainties and trade disputes. In such a volatile and uncertain market environment, investors mostly prefer to look for companies with robust fundamental data and convincing long -term growth perspectives. Three stocks that, according to Wall Street analysts, are currently particularly standing out, are ARM Holdings, Eli Lilly and Netflix. In all three companies, the experts see strong future prospects, as Tipranks explained – supported by innovative strength, leading market positions and stable growth forecasts.

Arm Holdings

ARM Holdings develops chip architectures for smartphones, cloud infrastructures and AI systems. Due to the growing need for energy -efficient computing technology, the company benefits particularly from its license -based business model, which is considered an important growth driver.

The quarter results of ARM, which are expected on May 7th, are likely to provide more information. According to Tipranks, analysts expect around 26 percent annual profit growth in the next three years.

In the previous course of the year, however, the share is volatile. The paper has lost 0.07 percent since the beginning of the year. In the past month, however, it was able to increase by a proud 40.54 percent. Most recently, the share cost $ 123.27 (as of 02.05.2025).

Despite a high price-profit ratio of around 130, many experts continue to recommend the share to buy- based on the increasing weight of arm in the AI ​​and data center area, Tipranks continues. The ambitious evaluation is also seen as an expression of trust in the corporate strategy and future development. Finally, 17 experts advised the shares to buy, while 4 experts have a stop recommendation and one advised for sale – which results in a moderate purchase recommendation. The average price target is $ 169.74 and thus corresponds to an upward potential of 37., 70 percent compared to the last course.

Eli Lilly

Eli Lilly increasingly open up a key player in the healthcare sector with innovative medication such as Mounjaro and Zepbound, as Tipranks explains. The two treatments against diabetes and obesity are considered potential sales drivers in billions of bills per year. In view of the strong demand and a promising product pipeline, analysts predict an average annual profit growth of 22.5 percent and a increase in sales of 15.3 percent.

On May 1st, Eli Lilly presented his financial results for the first quarter of this year. As can be seen from the press report, the company’s turnover rose by a total of 45 percent to $ 12.73 billion. The EPS also increased significantly. The profit per share increased by 23 percent to $ 3.06. However, the US pharmaceutical manufacturer capped his winning expectation for the full year due to depreciation.
Since the beginning of the year, the share has had a profit of 6.69 percent. And in the last month the numbers are also on green. The paper has increased by 11.57 percent in the past 30 days and most recently cost $ 823.62 (as of 02.05.2025).

Wall Street evaluates the company with the “Strong Buy” classification and sees clear further spa potential. In total, the stock received 19 purchase recommendations and only one sales recommendation in the past three months. The average price target is $ 983.81 and corresponds to a potential change of 19.45 percent compared to the last course.

Netflix

Netflix claims his leadership position in the streaming market and convinces with increasing number of subscribers and growing profits, writes Tipranks. Analysts in particular emphasize the successful introduction to the advertising -financed model and the improved cost structure, which contributes to higher operational margins.

Netflix significantly improved its business figures in the first quarter of 2025 and exceeded the expectations of the analysts. The profit per share increased to $ 6.76 compared to $ 5.40 in the previous year, and was therefore clear above the forecast of $ 5.67. The net profit increased by 24 percent to $ 2.89 billion. The company was also convincing when it comes to sales: the proceeds climbed from 9.37 to $ 10.54 billion-also slightly above the predicted $ 10.50 billion.
For the streaming provider’s share, things are going well in 2025. The price gains have been added to 29.75 percent since the beginning of the year. In the past month, the share certificate increased by 35.13 percent and most recently cost $ 1,156.49 (as of 02.05.2025).

The video streaming provider continues to play on the offensive, while the stock remains defensive, JPMorgan analyst Douglas wrote Grandh in a comment on the quarterly report. Results and outlook he regarded as a solid.

The first quarter of the streaming group went solid, also wrote UBS analyst John Hodulik in an assessment of the figures. In the second annual quarter, sales growth should accelerate.

As Tipranks explains, speculation is increasingly being made to achieve a market capitalization of $ 1 trillion by 2030. No wonder that the analysts are predominantly optimistic. The paper receives a strong purchase recommendation from 37 analyzes (29x buy, 8x hold). The average price target is $ 1,165.35 and thus corresponds to a possible change of 0.07 percent compared to the last course.

Editor finance.net

This text serves exclusively for information purposes and does not represent an investment recommendation. Finance.net GmbH excludes any regress entitlements.

Selected leverage products on arm

With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we show you suitable open-end products on arm

The lever must be between 2 and 20

Advertising